Genmab — Februar 2021
-
Måske det er voldgiften, der er taget ud af toplinien?
-
Revenue 6800-7500m
-
Operating restult dkk 1000-2000m for 2021
-
Dara guides til DARZALEX
royalties of DKK 4,900 – 5,300 million. -
GEN skriver selv om voldgiften ifht guidance: Given the ongoing arbitration, Genmab has reflected this as a reduction to estimated 2021 revenue.
-
Der er skåret i toplinjen...
-
Pokker JV
-
Men det kan jo ikke være meget ifht 2021 tallene - er det ikke 5% HALO får?
-
Glem det forlig. Det kommer ikke.
-
Er det ikke bare det almindelige forsigtighedsprincip, GEN bruger ifht guidance?
-
Jeg tænker ikke, at vi skal forbinde det alt for meget med et outcome af voldgiften
-
Enapotamab vedotin – data to support late stage development – development will not advance
-
Kunne det ikke se ud til, at omkostningerne ligger ca. 10% over forventet?
-
Share buy back - ud over dækning af warrants?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind